vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and MARRIOTT VACATIONS WORLDWIDE Corp (VAC). Click either name above to swap in a different company.
MARRIOTT VACATIONS WORLDWIDE Corp is the larger business by last-quarter revenue ($1.2B vs $708.5M, roughly 1.7× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -35.0%, a 54.1% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -0.7%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-6.0M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 5.2%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Marriott Vacations Worldwide Corporation is a pure-play public timeshare company. Formerly a division of Marriott International, Marriott Vacations Worldwide was established as a separate, publicly traded entity focusing primarily on vacation ownership in November 2011. Marriott Vacations Worldwide runs more than 120 resorts with over 700,000 Owners and members in a diverse portfolio of brands under The Marriott Vacation Clubs name. Its brands include Marriott Vacation Club, The Marriott Vaca...
MEDP vs VAC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $1.2B |
| Net Profit | $135.1M | $-431.0M |
| Gross Margin | — | — |
| Operating Margin | 21.6% | — |
| Net Margin | 19.1% | -35.0% |
| Revenue YoY | 32.0% | -0.7% |
| Net Profit YoY | 15.5% | -962.0% |
| EPS (diluted) | $4.65 | $-12.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $1.2B | ||
| Q3 25 | $659.9M | $1.2B | ||
| Q2 25 | $603.3M | $1.2B | ||
| Q1 25 | $558.6M | $1.1B | ||
| Q4 24 | $536.6M | $1.2B | ||
| Q3 24 | $533.3M | $1.2B | ||
| Q2 24 | $528.1M | $1.1B | ||
| Q1 24 | $511.0M | $1.1B |
| Q4 25 | $135.1M | $-431.0M | ||
| Q3 25 | $111.1M | $-2.0M | ||
| Q2 25 | $90.3M | $69.0M | ||
| Q1 25 | $114.6M | $56.0M | ||
| Q4 24 | $117.0M | $50.0M | ||
| Q3 24 | $96.4M | $84.0M | ||
| Q2 24 | $88.4M | $37.0M | ||
| Q1 24 | $102.6M | $47.0M |
| Q4 25 | 21.6% | — | ||
| Q3 25 | 21.5% | — | ||
| Q2 25 | 20.9% | — | ||
| Q1 25 | 20.3% | — | ||
| Q4 24 | 23.4% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 19.9% | — | ||
| Q1 24 | 20.4% | — |
| Q4 25 | 19.1% | -35.0% | ||
| Q3 25 | 16.8% | -0.2% | ||
| Q2 25 | 15.0% | 6.0% | ||
| Q1 25 | 20.5% | 5.0% | ||
| Q4 24 | 21.8% | 4.0% | ||
| Q3 24 | 18.1% | 6.9% | ||
| Q2 24 | 16.7% | 3.5% | ||
| Q1 24 | 20.1% | 4.2% |
| Q4 25 | $4.65 | $-12.00 | ||
| Q3 25 | $3.86 | $-0.07 | ||
| Q2 25 | $3.10 | $1.77 | ||
| Q1 25 | $3.67 | $1.46 | ||
| Q4 24 | $3.67 | $1.29 | ||
| Q3 24 | $3.01 | $2.12 | ||
| Q2 24 | $2.75 | $0.98 | ||
| Q1 24 | $3.20 | $1.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $406.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $2.0B |
| Total Assets | $2.0B | $9.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $406.0M | ||
| Q3 25 | $285.4M | $474.0M | ||
| Q2 25 | $46.3M | $205.0M | ||
| Q1 25 | $441.4M | $196.0M | ||
| Q4 24 | $669.4M | $197.0M | ||
| Q3 24 | $656.9M | $197.0M | ||
| Q2 24 | $510.9M | $206.0M | ||
| Q1 24 | $407.0M | $237.0M |
| Q4 25 | $459.1M | $2.0B | ||
| Q3 25 | $293.6M | $2.5B | ||
| Q2 25 | $172.4M | $2.5B | ||
| Q1 25 | $593.6M | $2.4B | ||
| Q4 24 | $825.5M | $2.4B | ||
| Q3 24 | $881.4M | $2.4B | ||
| Q2 24 | $763.6M | $2.4B | ||
| Q1 24 | $671.5M | $2.4B |
| Q4 25 | $2.0B | $9.8B | ||
| Q3 25 | $1.8B | $10.1B | ||
| Q2 25 | $1.6B | $9.9B | ||
| Q1 25 | $1.9B | $9.9B | ||
| Q4 24 | $2.1B | $9.8B | ||
| Q3 24 | $2.1B | $9.7B | ||
| Q2 24 | $1.9B | $9.6B | ||
| Q1 24 | $1.8B | $9.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $6.0M |
| Free Cash FlowOCF − Capex | $188.1M | $-6.0M |
| FCF MarginFCF / Revenue | 26.6% | -0.5% |
| Capex IntensityCapex / Revenue | 0.6% | 1.0% |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $-29.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $6.0M | ||
| Q3 25 | $246.2M | $62.0M | ||
| Q2 25 | $148.5M | $-48.0M | ||
| Q1 25 | $125.8M | $8.0M | ||
| Q4 24 | $190.7M | $100.0M | ||
| Q3 24 | $149.1M | $72.0M | ||
| Q2 24 | $116.4M | $30.0M | ||
| Q1 24 | $152.7M | $3.0M |
| Q4 25 | $188.1M | $-6.0M | ||
| Q3 25 | $235.5M | $51.0M | ||
| Q2 25 | $142.4M | $-68.0M | ||
| Q1 25 | $115.8M | $-6.0M | ||
| Q4 24 | $183.0M | $86.0M | ||
| Q3 24 | $138.5M | $58.0M | ||
| Q2 24 | $103.5M | $17.0M | ||
| Q1 24 | $147.2M | $-13.0M |
| Q4 25 | 26.6% | -0.5% | ||
| Q3 25 | 35.7% | 4.3% | ||
| Q2 25 | 23.6% | -5.9% | ||
| Q1 25 | 20.7% | -0.5% | ||
| Q4 24 | 34.1% | 6.9% | ||
| Q3 24 | 26.0% | 4.8% | ||
| Q2 24 | 19.6% | 1.6% | ||
| Q1 24 | 28.8% | -1.2% |
| Q4 25 | 0.6% | 1.0% | ||
| Q3 25 | 1.6% | 0.9% | ||
| Q2 25 | 1.0% | 1.7% | ||
| Q1 25 | 1.8% | 1.3% | ||
| Q4 24 | 1.4% | 1.1% | ||
| Q3 24 | 2.0% | 1.1% | ||
| Q2 24 | 2.4% | 1.2% | ||
| Q1 24 | 1.1% | 1.4% |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | -0.70× | ||
| Q1 25 | 1.10× | 0.14× | ||
| Q4 24 | 1.63× | 2.00× | ||
| Q3 24 | 1.55× | 0.86× | ||
| Q2 24 | 1.32× | 0.81× | ||
| Q1 24 | 1.49× | 0.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
VAC
| Cost Reimbursement | $467.0M | 38% |
| Time Share | $381.0M | 31% |
| Management And Exchange | $212.0M | 17% |
| Ancillary Revenues | $64.0M | 5% |
| Management Service | $55.0M | 4% |
| Service Other | $36.0M | 3% |
